Literature DB >> 19127586

What causes cell death in Parkinson's disease?

Amitabh Gupta1, Valina L Dawson, Ted M Dawson.   

Abstract

Currently, there is no proven neuroprotective or neurorestorative therapy for Parkinson's disease (PD). Several advances in the genetics of PD have created an opportunity to develop mechanistic-based therapies that hold particular promise for identifying agents that slow and even halt the progression of PD, as well as restore function. Here we review many of the advances in the last decade regarding the identification of new targets for the treatment of PD based on understanding the molecular mechanisms of how mutations in genes linked to PD cause neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19127586      PMCID: PMC4118469          DOI: 10.1002/ana.21573

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  119 in total

1.  Creatine and cyclocreatine attenuate MPTP neurotoxicity.

Authors:  R T Matthews; R J Ferrante; P Klivenyi; L Yang; A M Klein; G Mueller; R Kaddurah-Daouk; M F Beal
Journal:  Exp Neurol       Date:  1999-05       Impact factor: 5.330

2.  Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro.

Authors:  Kenjiro Ono; Mie Hirohata; Masahito Yamada
Journal:  J Neurosci Res       Date:  2007-05-15       Impact factor: 4.164

3.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.

Authors:  T Kitada; S Asakawa; N Hattori; H Matsumine; Y Yamamura; S Minoshima; M Yokochi; Y Mizuno; N Shimizu
Journal:  Nature       Date:  1998-04-09       Impact factor: 49.962

4.  Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein.

Authors:  Igor F Tsigelny; Pazit Bar-On; Yuriy Sharikov; Leslie Crews; Makoto Hashimoto; Mark A Miller; Steve H Keller; Oleksandr Platoshyn; Jason X-J Yuan; Eliezer Masliah
Journal:  FEBS J       Date:  2007-04       Impact factor: 5.542

5.  An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model.

Authors:  M Hashimoto; E Rockenstein; M Mante; L Crews; P Bar-On; F H Gage; R Marr; E Masliah
Journal:  Gene Ther       Date:  2004-12       Impact factor: 5.250

Review 6.  The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation.

Authors:  Toshiaki Inoue; Masaharu Hiratsuka; Mitsuhiko Osaki; Mitsuo Oshimura
Journal:  Cell Cycle       Date:  2007-05-30       Impact factor: 4.534

7.  Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions.

Authors:  S Engelender; Z Kaminsky; X Guo; A H Sharp; R K Amaravi; J J Kleiderlein; R L Margolis; J C Troncoso; A A Lanahan; P F Worley; V L Dawson; T M Dawson; C A Ross
Journal:  Nat Genet       Date:  1999-05       Impact factor: 38.330

Review 8.  Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis.

Authors:  M F Beal
Journal:  Ann Neurol       Date:  1998-09       Impact factor: 10.422

9.  The R1441C mutation of LRRK2 disrupts GTP hydrolysis.

Authors:  Patrick A Lewis; Elisa Greggio; Alexandra Beilina; Shushant Jain; Acacia Baker; Mark R Cookson
Journal:  Biochem Biophys Res Commun       Date:  2007-04-10       Impact factor: 3.575

10.  Mutation of the linker region of the polymerase gamma-1 (POLG1) gene associated with progressive external ophthalmoplegia and Parkinsonism.

Authors:  Gavin Hudson; Andrew M Schaefer; Robert W Taylor; Watcharee Tiangyou; Andrew Gibson; Graham Venables; Philip Griffiths; David J Burn; Douglass M Turnbull; Patrick F Chinnery
Journal:  Arch Neurol       Date:  2007-04
View more
  54 in total

Review 1.  Recent advances in the genetics of Parkinson's disease.

Authors:  Ian Martin; Valina L Dawson; Ted M Dawson
Journal:  Annu Rev Genomics Hum Genet       Date:  2011       Impact factor: 8.929

Review 2.  PGC-1α: a master gene that is hard to master.

Authors:  Dan Lindholm; Ove Eriksson; Johanna Mäkelä; Natale Belluardo; Laura Korhonen
Journal:  Cell Mol Life Sci       Date:  2012-06-09       Impact factor: 9.261

Review 3.  Missing pieces in the Parkinson's disease puzzle.

Authors:  Jose A Obeso; Maria C Rodriguez-Oroz; Christopher G Goetz; Concepcion Marin; Jeffrey H Kordower; Manuel Rodriguez; Etienne C Hirsch; Matthew Farrer; Anthony H V Schapira; Glenda Halliday
Journal:  Nat Med       Date:  2010-05-23       Impact factor: 53.440

4.  Homozygosity for the MTX1 c.184T>A (p.S63T) alteration modifies the age of onset in GBA-associated Parkinson's disease.

Authors:  Ziv Gan-Or; Anat Bar-Shira; Tanya Gurevich; Nir Giladi; Avi Orr-Urtreger
Journal:  Neurogenetics       Date:  2011-08-12       Impact factor: 2.660

5.  Activation of ataxia telangiectasia muted under experimental models and human Parkinson's disease.

Authors:  Antoni Camins; Javier G Pizarro; Daniel Alvira; Javier Gutierrez-Cuesta; Aurelio Vazquez de la Torre; Jaume Folch; Francesc X Sureda; Ester Verdaguer; Felix Junyent; Joaquín Jordán; Isidre Ferrer; Mercè Pallàs
Journal:  Cell Mol Life Sci       Date:  2010-05-26       Impact factor: 9.261

Review 6.  Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease.

Authors:  D James Surmeier; Glenda M Halliday; Tanya Simuni
Journal:  Exp Neurol       Date:  2017-08-02       Impact factor: 5.330

7.  The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition.

Authors:  Virginie Loeb; Eugenia Yakunin; Ann Saada; Ronit Sharon
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

Review 8.  Current disease modifying approaches to treat Parkinson's disease.

Authors:  Dan Lindholm; Johanna Mäkelä; Valentina Di Liberto; Giuseppa Mudò; Natale Belluardo; Ove Eriksson; Mart Saarma
Journal:  Cell Mol Life Sci       Date:  2015-11-30       Impact factor: 9.261

9.  Pro-survival role for Parkinson's associated gene DJ-1 revealed in trophically impaired dopaminergic neurons.

Authors:  Liviu Aron; Pontus Klein; Thu-Trang Pham; Edgar R Kramer; Wolfgang Wurst; Rüdiger Klein
Journal:  PLoS Biol       Date:  2010-04-06       Impact factor: 8.029

10.  Parkinson's disease brain mitochondria have impaired respirasome assembly, age-related increases in distribution of oxidative damage to mtDNA and no differences in heteroplasmic mtDNA mutation abundance.

Authors:  Charles R Arthur; Stephanie L Morton; Lisa D Dunham; Paula M Keeney; James P Bennett
Journal:  Mol Neurodegener       Date:  2009-09-23       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.